CERS - Cerus Corporation logo

Cerus Corporation

CERS

Cerus Corporation develops and commercializes the INTERCEPT Blood System, a technology designed to inactivate blood-borne pathogens in donated blood components, including platelets, plasma, and red blood cells, enhancing blood safety for transfusions.

βš•οΈ Healthcare NASDAQ Listed 1997 $ USD
$1,000 invested 20 years ago β†’$429today

Score Overview

1 Year
Score
Net Growth56.59%
Net TrendGrew
Net Income Consistencyβ€”
Rev Growth10.50%
Rev TrendGrew
Revenue Consistencyβ€”
5 Years
Score7.9
Net Growth87.53%
Net TrendEvery year
Net Income Consistencyβ€”
Rev Growth74.07%
Rev Trend80%
Revenue Consistencyβ€”
10 Years
Score
Net Growth89.22%
Net Trend90%
Net Income Consistency
Rev Growth6x
Rev Trend90%
Revenue Consistency
20 Years
Score4.7
Net Growth-41.93%
Net Trend70%
Net Income Consistency
Rev Growth6x
Rev Trend80%
Revenue Consistency
All Time
Score
Net Growth53.86%
Net Trend59%
Net Income Consistency
Rev Growth33x
Rev Trend76%
Revenue Consistency

Explore the 2021 public Archive ranking β†’

Where Cerus Corporation has ranked, year by year

Measure
Fundamentals Window

Showing 5 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • CERS

2003: 98.3% Β· 2021: 42.6% Β· free through 2021 Β· longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-30
$ 2.38β€”
1 Year2025-09-30
$ 1.5949.69%
5 Years2021-09-30
$ 6.09-60.92%
10 Years2016-09-30
$ 6.21-61.67%
20 Years2006-09-29
$ 5.55-57.12%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 227M-$ 6M$ 56M
2025$ 206M-$ 15M$ 82M
2024$ 180M-$ 20M$ 80M
2023$ 156M-$ 37M$ 65M
2022$ 162M-$ 42M$ 102M
2021$ 130M-$ 54M$ 129M
2020$ 91M-$ 59M$ 133M
2019$ 74M-$ 71M$ 85M
2018$ 60M-$ 57M$ 117M
2017$ 43M-$ 60M$ 60M
2016$ 37M-$ 62M$ 71M
2015$ 34M-$ 55M$ 107M
2014$ 36M-$ 38M$ 51M
2013$ 39M-$ 43M$ 57M
2012$ 36M-$ 15M$ 26M
2011$ 33M-$ 16M$ 25M
2010$ 23M-$ 16M$ 30M
2009$ 17M-$ 24M$ 19M
2008$ 16M-$ 29M$ 22M
2007$ 11M-$ 45M$ 56M
2006$ 35M-$ 4M$ 93M
2005$ 24M$ 13M$ 45M
2004$ 13M-$ 31M$ 95M
2003$ 9M-$ 58M$ 110M
2002$ 8M-$ 57M$ 64M
2001$ 4M-$ 49M$ 123M
2000$ 1M-$ 36M$ 90M
1999$ 2M-$ 22M$ 40M
1998$ 2M-$ 29M$ 6M
IPO1997$ 6M-$ 14M$ 11M
CERS - Cerus Corporation logo

Cerus Corporation fundamental performance

Between 2020 and 2025, revenue grew from $ 91M to $ 206M and net income went from -$ 59M to -$ 15M. Revenue increased in 4 of those 5 years; net income in every one.

Between 2015 and 2025, revenue grew from $ 34M to $ 206M and net income went from -$ 55M to -$ 15M. Revenue increased in 9 of those 10 years; net income in 9.

Cerus Corporation currently holds a 20-year HDB Score of 4.7 out of 10. How the HDB Score is calculated.

Membership

Continue CERS’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year Β· Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies